Filoviridae

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 8, 2023
Massachusetts General Hospital, VIC, Research, Insurance, Health, Infection, Vaccine, Enzyme, RNA, Department of Defense Serum Repository, Business development, Biofuel, Livestock, Protein, Filoviridae, EDCL, MHCII, Clinical trial, COVID-19, Webcast, Department of Defence, Business, Messenger, SAS, Animal, Phibro, Safety, Negotiation, Microsoft, Hospital, D, Cryptocurrency, Fine chemical, Pharmaceutical industry, Life insurance, C1, Dyadic

Phase 1 clinical trial, last patient last visit occurred in September, data lock achieved on November 1, 2023 and top-line results are expected in December 2023 with full study report to follow.

Key Points: 
  • Phase 1 clinical trial, last patient last visit occurred in September, data lock achieved on November 1, 2023 and top-line results are expected in December 2023 with full study report to follow.
  • Interim phase 1 clinical trial safety results are helping to accelerate the adoption of our C1 protein production platform in use for manufacturing human vaccines.
  • In October 2023, the Company received an upfront payment of $0.6 million for product development.
  • The Company is making progress in developing animal-free recombinant serum albumin with initial positive analytical results towards commercialization and prospective licensing opportunities.

Sabin Vaccine Institute Receives Additional $34.5 Million from BARDA for Further Development of Ebola Sudan and Marburg Vaccines

Retrieved on: 
Thursday, October 21, 2021
Safety, Death, Research, DRC, Assistant, Vaccine Research Center, Ecosystem, Filoviridae, Vaccine, Disease, Sabin, Marburg virus disease, Military personnel, Sabin Vaccine Institute, Viral hemorrhagic fever, Public Health Emergency of International Concern, Human, BARDA, Twitter, Partnership, Virus, Ebola River, Ebola, Primate, World Health Organization, Public health emergency, World, Ministry of Health (Saudi Arabia), Policy, Office of the Assistant Secretary for Preparedness and Response, Office of Inspector General, U.S. Department of Health and Human Services, Ministry, Biomedical Advanced Research and Development Authority, Polio, Infection, Public health, COVID-19, WHO, Solution, Development, GSK, GLOBE, Animal, Pharmaceutical industry

In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million.

Key Points: 
  • In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million.
  • The two candidate vaccines, based on GSKs proprietary ChAd3 platform, were exclusively licensed to the Sabin Vaccine Institute from GSK in 2019.
  • Ebola Sudan and Marburg are members of the Filoviridae virus family and are commonly referred to as filoviruses.
  • Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and southern Sudan.

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting

Retrieved on: 
Thursday, July 22, 2021
Medical specialties, Animal diseases, Infectious diseases, Zoonoses, Biological weapons, Tropical diseases, Sudan ebolavirus, Ebolavirus, Ebola, GeoVax, Zaire ebolavirus, Filoviridae

ATLANTA, GA, July 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines, today announced the presentation of data from a study of its preventive vaccine against Sudan Ebolavirus (SUDV). The presentation titled “A single immunization of guinea pigs with a modified vaccinia Ankara virus producing Sudan virus-like particles protects from Sudan virus lethal challenge,” was delivered by Dr. Delphine Malherbe of the Bukreyev Lab, Department of Pathology, University of Texas Medical Branch, Galveston, Texas, during the Annual Meeting of the American Society for Virology, being held virtually July 19-23.

Key Points: 
  • Challenge of vaccinated animals with guinea pig-adapted SUDV demonstrated a complete protection against death and disease by the prime and the prime-boost regimens.
  • This is the first report that a replication-deficient MVA vector may confer full protection against SUDV after a single dose.
  • David Dodd, GeoVax President and CEO, further commented, The presentation of data from this study further validates our platform and approach to addressing Sudan virus, and we look forward to advancing our vaccine to non-human primate testing.
  • Sudan ebolavirus (SUDV) is one of six known viruses within the genus Ebolavirus (Filoviridae family) and causes Ebola virus disease in humans, with a fatality rate up to 73%.

Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses

Retrieved on: 
Tuesday, July 13, 2021
Medical specialties, Zoonoses, Medicine, Clinical medicine, Biological weapons, Tropical diseases, Antiviral drug, Biocides, Filoviridae, Alphavirus, Arenavirus, Virus

DOYLESTOWN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents.

Key Points: 
  • DOYLESTOWN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents.
  • The proposed drug intends to improve disease survival after exposure to one or more viruses from three families: alphaviruses, arenaviruses and filoviruses.
  • The DODs Defense Threat Reduction Agencys Chem Bio Technologies, Vaccines and Therapeutics Division executed an Other Transaction Authority (OTA) agreement with Evrys for this effort.
  • EVRYS stands for the Companys vision to ultimately address every virus, said Lillian Chiang, PhD, CEO, Evrys Bio.

Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens

Retrieved on: 
Tuesday, September 15, 2020
Medical specialties, Animal diseases, Veterinary medicine, Biological weapons, Tropical diseases, Zoonoses, Animal virology, Ebolavirus, Sudan ebolavirus, Filoviridae, Ebola, Zaire ebolavirus

These most recent results demonstrate the thermostabilization of three virus glycoproteins (from Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus), and the identification of key stability-indicating assays to further support mono-, bi- and tri-valent vaccine formulations.

Key Points: 
  • These most recent results demonstrate the thermostabilization of three virus glycoproteins (from Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus), and the identification of key stability-indicating assays to further support mono-, bi- and tri-valent vaccine formulations.
  • "The continued advances in the filovirus program demonstrates the program's maturity and overall developability," noted Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer of Soligenix.
  • "The compatibility with thermostabilization, and the identification of key stability indicating assays, are both hallmarks of a potentially broadly applicable vaccine platform.
  • Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines

Retrieved on: 
Thursday, August 13, 2020
Medical specialties, Infectious diseases, Animal diseases, Tropical diseases, Zoonoses, Biological weapons, Sudan ebolavirus, Ebolavirus, Zaire ebolavirus, Filoviridae, Ebola, Marburg virus disease

ATLANTA, GA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today a multi-party collaboration for the development of Sudan ebolavirus (SUDV) and Marburg virus (MARV) vaccine candidates.

Key Points: 
  • ATLANTA, GA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today a multi-party collaboration for the development of Sudan ebolavirus (SUDV) and Marburg virus (MARV) vaccine candidates.
  • David Dodd, GeoVax President and CEO, commented, This exciting collaboration enables us to advance these two critically needed vaccine candidates through nonhuman primate testing.
  • Sudan ebolavirus (SUDV) is one of six known viruses within the genus Ebolavirus (Filoviridae family) and causes Ebola virus disease in humans, with a fatality rate as high as 71%.
  • GeoVaxs current development programs are focused on preventive vaccines against COVID-19, HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against solid tumor cancers.

BioFactura Awarded $1 Million SBIR Contract for Development of a Marburg Virus Therapeutic

Retrieved on: 
Thursday, July 30, 2020
Medical specialties, Medicine, Clinical medicine, Biological weapons, Tropical diseases, Zoonoses, Animal virology, Filoviridae, Marburg virus disease, Marburg virus, Ebolavirus, Monoclonal antibody

With so much focus on Ebolavirus over the last few years, MARV antibody development efforts have lagged considerably and few MARV-specific mAbs have been described.

Key Points: 
  • With so much focus on Ebolavirus over the last few years, MARV antibody development efforts have lagged considerably and few MARV-specific mAbs have been described.
  • Dr. Darryl Sampey, President and CEO of BioFactura, stated, "This Chem-Bio Defense Phase II award builds upon our successful early development of a highly productive StableFast cell line during the SBIR Phase I contract.
  • "This government contract for the development of a novel Marburg virus therapeutic countermeasure is the result of continued efforts to create highly effective therapeutics that can be deployed in the event of a biological threat.
  • For over 15 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies.

Global Pipeline Review for Ebolavirus Infections (Ebola Hemorrhagic Fever), H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 22, 2020
Health, Infectious diseases, Infectious diseases, Medical specialties, Medicine, Tropical diseases, Biological weapons, Zoonoses, Animal virology, Ebolavirus, Filoviridae, Ebola virus disease, Virus, Viral hemorrhagic fever

The "Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections pipeline depth and focus of Indication therapeutics.